Finoriq research workspace
Apogee Therapeutics, Inc. (APGE) Historical Metrics
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the. Review APGE fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
- Company
- Apogee Therapeutics, Inc. (APGE)
- Ticker
- APGE
- Market Cap
- $10.1B
- Latest Price
- $134.18
- Industry
- Biotech & Pharma
Apogee Therapeutics, Inc. (APGE) Current Valuation Metrics
Static valuation preview for Apogee Therapeutics, Inc. (APGE). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -2.5% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -2.3% | Operating Cash Flow | TTM FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.